Navigation Links
PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
Date:12/7/2011

ator of which is the average closing price of PDL's common stock for the 10 consecutive trading days immediately preceding the ex-dividend date of December 6, 2011, for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements
The foregoing statements regarding PDL's intentions with respect to the cash dividend payment described above constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2010 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2011, and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Windhover Announces the "Top Biopharma Projects to Watch"
3. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
4. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
6. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
7. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
8. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. PDL BioPharma Announces Second Quarter 2011 Financial Results on July 27, 2011
11. Genesis Biopharma Names David Voyticky to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... TX (PRWEB) December 17, 2014 Achim ... and administration for Stoller Group. In this position, Noack ... Group, on administrative matters, develop marketing strategy and supervise ... services. , “Achim has tremendous knowledge and experience ... of Stoller Group. “His experience and innovative thinking will ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... 2011 BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products marketed as XIAFLEX ® in the U.S. ... announced the appointment of  George Gould, Esq., to its ... an attorney, is Principal of George M. Gould, LLC, ...
... 2011  Janssen Biotech, Inc., one of the Janssen Pharmaceutical ... ), announced today that it has executed an agreement ... jointly develop and market the anti-cancer compound, PCI-32765.  A ... are ongoing across a panel of B-cell malignancy disorders, ...
... December 8, 2011 The Joint Management ... (ENPI CBC MED program) has informed Prof Nava ... they will award a contract of up to 2 ... and directed by Hadassah College, will be implemented in ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 2Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 3The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Adoptive cell transfer (ACT) therapy is used to treat patients ... of the patient's cancer cells, and some of their immune ... of the cancer cells that stimulate the T cells to ... get expanded and re-infused into the patient to mount an ...
... pandemic influenza, a new study reports for the first time ... from poultry to humans. The research appears in the ... available online. , Crossing the species barrier is an important ... potential. Previous studies have focused on the ability of highly ...
... many scientists thought, genetically modified (GM) corn has not ... , After analyzing tens of thousands of seeds from ... Mexico and the United States found no evidence of ... the researchers, said Allison Snow, a professor of evolution, ...
Cached Biology News:First Whole Genome Map of Genetic Variability in Parkinson’s Disease 2Genetically modified maize not found in southern Mexico 2
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 100 mL...
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: